|
1
|
Santibáñez M, Garrastazu R, Ruiz-Nuñez M,
Helguera JM, Arenal S, Bonnardeux C, León C and García-Rivero JL:
Predictors of hospitalized exacerbations and mortality in chronic
obstructive pulmonary disease. PLoS One. 11:e01587272016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wain LV, Shrine N, Artigas MS,
Erzurumluoglu AM, Noyvert B, Bossini-Castillo L, Obeidat M, Henry
AP, Portelli MA, Hall RJ, et al Understanding Society Scientific
Group; Geisinger-Regeneron DiscovEHR Collaboration, : Genome-wide
association analyses for lung function and chronic obstructive
pulmonary disease identify new loci and potential druggable
targets. Nat Genet. 49:416–425. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou Y, Zhong NS, Li X, Chen S, Zheng J,
Zhao D, Yao W, Zhi R, Wei L, He B, et al: Tiotropium in early-stage
chronic obstructive pulmonary disease. N Engl J Med. 377:923–935.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jinjuvadia C, Jinjuvadia R, Mandapakala C,
Durairajan N, Liangpunsakul S and Soubani AO: Trends in outcomes,
financial burden, and mortality for acute exacerbation of chronic
obstructive pulmonary disease (COPD) in the United States from 2002
to 2010. COPD14. 72–79. 2017. View Article : Google Scholar
|
|
5
|
Cebron Lipovec N, Beijers RJ, van den
Borst B, Doehner W, Lainscak M and Schols AM: The prevalence of
metabolic syndrome in chronic obstructive pulmonary disease: A
systematic review. COPD. 13:399–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
US Preventive Services Task Force
(USPSTF), ; Siu AL, Bibbins-Domingo K, Grossman DC, Davidson KW,
Epling JW Jr, García FA, Gillman M, Kemper AR, Krist AH, et al:
Screening for chronic obstructive pulmonary disease: US Preventive
Services Task Force recommendation statement. JAMA. 315:1372–1377.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan DBA, Armitage J, Teo TH, Ong NE, Shin
H and Moodley YP: Elevated levels of circulating exosome in COPD
patients are associated with systemic inflammation. Respir Med.
132:261–264. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soler-Cataluña JJ, Martínez-García MA,
Román Sánchez P, Salcedo E, Navarro M and Ochando R: Severe acute
exacerbations and mortality in patients with chronic obstructive
pulmonary disease. Thorax. 60:925–931. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takase H, Tanaka M, Yamamoto A, Watanabe
S, Takahashi S, Nadanaka S, Kitagawa H, Yamada T and Mukai T:
Structural requirements of glycosaminoglycans for facilitating
amyloid fibril formation of human serum amyloid A. Amyloid.
23:67–75. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siegmund SV, Schlosser M, Schildberg FA,
Seki E, De Minicis S, Uchinami H, Kuntzen C, Knolle PA, Strassburg
CP and Schwabe RF: Serum amyloid a induces inflammation,
proliferation and cell death in activated hepatic stellate cells.
PLoS One. 11:e01508932016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park
CS, Park JY, Lee SY, Kim JW and Cho JY: Identification and
validation of SAA as a potential lung cancer biomarker and its
involvement in metastatic pathogenesis of lung cancer. J Proteome
Res. 10:1383–1395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schaper F and Rose-John S: Interleukin-6:
Biology, signaling and strategies of blockade. Cytokine Growth
Factor Rev. 26:475–487. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M,
Shahveranov A, Ye DW and Tian YK: Interleukin-6: An emerging
regulator of pathological pain. J Neuroinflammation. 13:1412016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jordan SC, Choi J, Kim I, Wu G, Toyoda M,
Shin B and Vo A: Interleukin-6, a cytokine critical to mediation of
inflammation, autoimmunity and allograft rejection: Therapeutic
implications of IL-6 receptor blockade. Transplantation. 101:32–44.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rothaug M, Becker-Pauly C and Rose-John S:
The role of interleukin-6 signaling in nervous tissue. Biochim
Biophys Acta 1863A. 1218–1227. 2016. View Article : Google Scholar
|
|
16
|
Lopez-Campos JL, Calero-Acuña C,
Lopez-Ramirez C, Abad-Arranz M, Márquez-Martín E, Ortega-Ruiz F and
Arellano E: Implications of the inflammatory response for the
identification of biomarkers of chronic obstructive pulmonary
disease. Biomark Med. 10:109–122. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miravitlles M, Soler-Cataluña JJ, Calle M,
Molina J, Almagro P, Quintano JA, Trigueros JA, Cosío BG, Casanova
C, Antonio Riesco J, et al: Spanish Guidelines for Management of
Chronic Obstructive Pulmonary Disease (GesEPOC) 2017.
Pharmacological treatment of stable phase. Arch Bronconeumol.
53:324–335. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vogelmeier CF, Criner GJ, Martínez FJ,
Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M,
Fabbri LM, et al: Global strategy for the diagnosis, management,
and prevention of chronic obstructive lung disease 2017 report.
GOLD executive summary. Am J Respir Crit Care Med. 195:557–582.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dalal AA, Christensen L, Liu F and Riedel
AA: Direct costs of chronic obstructive pulmonary disease among
managed care patients. Int J Chron Obstruct Pulmon Dis. 5:341–349.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seemungal TA, Donaldson GC, Paul EA,
Bestall JC, Jeffries DJ and Wedzicha JA: Effect of exacerbation on
quality of life in patients with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med. 157:1418–1422. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dransfield MT, Kunisaki KM, Strand MJ,
Anzueto A, Bhatt SP, Bowler RP, Criner GJ, Curtis JL, Hanania NA,
Nath H, et al COPD Gene Investigators, : Acute exacerbations and
lung function loss in smokers with and without chronic obstructive
pulmonary disease. Am J Respir Crit Care Med. 195:324–330.
2017.PubMed/NCBI
|
|
22
|
Frame NM and Gursky O: Structure of serum
amyloid A suggests a mechanism for selective lipoprotein binding
and functions: SAA as a hub in macromolecular interaction networks.
FEBS Lett. 590:866–879. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sack GH Jr: Serum amyloid A - a review.
Mol Med. 24:462018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
De Buck M, Gouwy M, Wang JM, Van Snick J,
Opdenakker G, Struyf S and Van Damme J: Structure and expression of
different serum amyloid A (SAA) variants and their
concentration-dependent functions during host insults. Curr Med
Chem. 23:1725–1755. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun L and Ye RD: Serum amyloid A1:
Structure, function and gene polymorphism. Gene. 583:48–57. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
De Buck M, Gouwy M, Wang JM, Van Snick J,
Proost P, Struyf S and Van Damme J: The cytokine-serum amyloid
A-chemokine network. Cytokine Growth Factor Rev. 30:55–69. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jensen LE and Whitehead AS: Regulation of
serum amyloid A protein expression during the acute-phase response.
Biochem J. 334:489–503. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Heo TH, Wahler J and Suh N: Potential
therapeutic implications of IL-6/IL-6R/gp130-targeting agents in
breast cancer. Oncotarget. 7:15460–15473. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmidt-Arras D and Rose-John S: IL-6
pathway in the liver: From physiopathology to therapy. J Hepatol.
64:1403–1415. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang Z and Zhu L: Update on molecular
mechanisms of corticosteroid resistance in chronic obstructive
pulmonary disease. Pulm Pharmacol Ther. 37:1–8. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu X, Jones GW, Choy EH and Jones SA: The
biology behind interleukin-6 targeted interventions. Curr Opin
Rheumatol. 28:152–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li W, Zhou Y and Zhang T: Expressions of
serum TSLP, SAA, and CRP in COPD patients. J Chin Physician.
20:46–49. 2018.
|
|
33
|
Chen YWR, Leung JM and Sin DD: A
systematic review of diagnostic biomarkers of COPD exacerbation.
PLoS One. 11:e01588432016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Landi A, Broadhurst D, Vernon SD, Tyrrell
DL and Houghton M: Reductions in circulating levels of IL-16, IL-7
and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome.
Cytokine. 78:27–36. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Flores RJ: The use of circulating SAA and
CXCL4 to predict outcome of osteosarcoma at diagnosis. Cancer Res.
76:4592016.
|
|
36
|
Fu G-Q, Xia J and Wang G: Clinical values
of SAA and hs-CRP in the diagnosis of postoperative infection in
patients with ovarian tumor. Zhongguo Jiceng Yiyao. 24:1069–1072.
2017.(In Chinese).
|
